Isuzu’s first battery-electric pickup “D-MAX EV” adopts eAxle

KARIYA, JAPAN, August 1, 2025 – (JCN Newswire via SeaPRwire.com) – BluE Nexus Corporation (headquartered in Anjo, Aichi; Hidetoshi Uchiyama, president; hereinafter “BluE”), AISIN Corporation (headquartered in Kariya, Aichi; Moritaka Yoshida, president; hereinafter “AISIN”), and DENSO CORPORATION (headquartered in Kariya, Aichi; […]

Revenue of LEQEMBI(R) (Preliminary Basis)

TOKYO, July 31, 2025 – (JCN Newswire via SeaPRwire.com) – Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) announced today that the global revenue(pre-audit basis) of the anti-amyloid-beta protofibril antibody “LEQEMBI®” (generic name: lecanemab) was JPY 23.1 billion for the […]

DENSO Announces First Quarter Financial Results

KARIYA, JAPAN, July 31, 2024 – (JCN Newswire via SeaPRwire.com) – DENSO, a leading mobility supplier, today announced global financial results for the first quarter, ending June 30, 2025, of its fiscal year, ending March 31, 2026: Consolidated revenue totaled […]

New Data Presented at AAIC Demonstrates Investigational LEQEMBI(R) (lecanemab-irmb) 360 mg Subcutaneous Maintenance Dosing Could Offer a New Option for Ongoing Treatment of Early Alzheimer’s Disease

TOKYO and CAMBRIDGE, Mass., July 31, 2025 – (JCN Newswire via SeaPRwire.com) – Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”)and Biogen Inc. (Nasdaq: BIIB, Headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher,“Biogen”) announced today that results on investigational maintenance therapy […]

Collaborative Development of Ultra-Compact and Lightweight Satellite Communication User Terminals for Mobility with Mitsubishi Chemical, NICT, and TECHLAB

TOKYO, July 30, 2025 – (JCN Newswire via SeaPRwire.com) – Sharp Corporation has reached an agreement with Mitsubishi Chemical Corporation (Headquarters: Chiyoda-ku, Tokyo; President: Manabu Tsukimoto), the National Institute of Information and Communications Technology (NICT) (Headquarters: Koganei City, Tokyo; President: […]

LENVIMA(R) (lenvatinib) in Combination with Pembrolizumab and Transarterial Chemoembolization (TACE) Approved in China for the Treatment of Unresectable, Non-Metastatic Hepatocellular Carcinoma

TOKYO, July 29, 2025 – (JCN Newswire via SeaPRwire.com) – Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) announced today that its in-house discovered tyrosine kinase inhibitor, “LENVIMA®” (generic name: lenvatinib mesylate), in combination with the anti-PD-1 antibody, pembrolizumab, […]

Launch of Beova(R) Tablets in Thailand for Overactive Bladder

TOKYO, July 23, 2025 – (JCN Newswire via SeaPRwire.com) – Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and KYORIN Pharmaceutical Co., Ltd.(Headquarters: Chiyoda-ku, Tokyo, President and CEO: Yutaka Ogihara, “KYORIN”) announced today that Eisai (Thailand) Marketing Co., Ltd. (“Eisai […]